Drug Trial Radar · NCT06358950
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Mar 24, 2024
Primary completion
Jun 19, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.
Conditions
- Narcolepsy Type 1
Interventions
ALKS 2680Drug
Oral tablet of ALKS 2680 for once daily administration
PlaceboDrug
Oral tablet containing matching placebo for once daily administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Sleep Latency (MSL) on the Maintenance of Wakefulness Test (MWT) from baseline to Week 6Time frame: Baseline to Week 6
Locations
45 sites in 8 countries. Site status is shown where the registry gives one.
Alkermes Investigational Site
Los Angeles, California
Alkermes Investigational Site
Redwood City, California
Alkermes Investigator Site
San Francisco, California
Alkermes Investigational Site
Santa Ana, California
Alkermes Investigational Site
Aurora, Colorado
Alkermes Investigational Site
Colorado Springs, Colorado
Alkermes Investigational Site
Brandon, Florida
Alkermes Investigator Site
Brandon, Florida
Alkermes Investigational Site
Miami, Florida
Alkermes Investigator Site
Winter Park, Florida
Alkermes Investigational Site
Atlanta, Georgia
Alkermes Investigational Site
Macon, Georgia
Alkermes Investigational Site
Stockbridge, Georgia
Alkermes Investigator Site
Peoria, Illinois
Alkermes Investigator Site
Lansing, Michigan
Alkermes Investigator Site
Sterling Heights, Michigan
Alkermes Investigator Site
Lincoln, Nebraska
Alkermes Investigational Site
Middletown, New Jersey
Alkermes Investigational Site
Denver, North Carolina
Alkermes Investigational Site
Huntersville, North Carolina
Alkermes Investigator Site
Canton, Ohio
Alkermes Investigational Site
Cincinnati, Ohio
Alkermes Investigational Site
Cincinnati, Ohio
Alkermes Investigational Site
Dublin, Ohio
Alkermes Investigational Site
Wyomissing, Pennsylvania
Alkermes Investigational Site
Columbia, South Carolina
Alkermes Investigational Site
Austin, Texas
Alkermes Investigational Site
San Antonio, Texas
Alkermes Investigational Site
The Woodlands, Texas
Alkermes Investigator Site
Macquarie Park, New South Wales, Australia
Alkermes Investigator Site
Bedford Park, South Australia, Australia
Alkermes Investigational Site
Alken, Belgium
Alkermes Investigational Site
Bruges, Belgium
Alkermes Investigational Site
Namur, Belgium
Alkermes Investigational Site
Prague, Czechia
Alkermes Investigational Site
Bordeaux, France
Alkermes Investigational Site
Montpellier, France
Alkermes Investigational Site
Bologna, Italy
Alkermes Investigational Site
Milan, Italy
Alkermes Investigational Site
Verona, Italy
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.